The aim of the study was to investigate the safety and efficacy of using @entity22757 in the treatment of @entity1538 ( @entity1538 ).This prospective cohort included subjects >= 18 years of age with @entity1538 , defined as the open angle on gonioscopy with @entity1781 evident from optical coherence tomography. Subjects with IOP<21mm Hg were classified as normal tension @entity726 and those with IOP >= 21mm Hg were classified as primary @entity1538 . Those with angle closure, secondary @entity726 , prior laser trabeculoplasty, use of systemic IOP-lowering medications, corneal pathologies, follow-up <6 months, recent intraocular surgery, or only 1 functional eye were excluded. A single session of unilateral @entity22757 treatment was delivered using a 577nm diode laser to 360   of the trabecular meshwork to reduce IOP or medication load. Medications were titrated up or down at 1 month after laser to achieve a 25% IOP reduction from presentation or an IOP <18mm Hg, whichever was lower. The following were compared using the Repeated Measures ANOVA with Bonferroni's Multiple Comparison Test: IOP (on presentation, pre- @entity22757 , day 1, 1 week, 1 month, 3 months, and 6 months after @entity22757 ) and the number of medications (pre- @entity22757 , 3 months, and 6 months after @entity22757 ). After 6 months, responders with initial success to @entity22757 (IOP reduction >= 20% at 1 month) received treatment in the fellow eye.In 48 subjects with @entity1538 , the mean number of @entity22757 shots applied was 120.5  2.0 shots using a mean energy of 1000mW per shot. Only 7.5% had a mild, self-limiting anterior @entity1596 postlaser with no change in the Snellen visual acuity at 6 months (P's>0.5). The IOP and number of medications were significantly reduced at all time intervals following @entity22757 compared to the pre- @entity22757 level (P's<0.0001). At 6 months, the IOP was reduced by 19.5% in addition to a 21.4% reduction in medication compared to pretreatment levels. The @entity22757 success rate was 72.9%. During the first 6 months only 2.1% required a repeated laser trabeculoplasty. @entity22757 was effective in reducing IOP and medications in @entity1538 with minimal postlaser inflammation and low failure rate at 6 months following laser.

MicroPulse Laser Trabeculoplasty for the Treatment of XXXX .

@entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma', 'OAG'] @entity1596 :: ('MESH:D014605', 'Disease') :: ['uveitis'] @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma'] @entity22757 :: ('51776', 'Gene') :: ['MLT'] @entity1781 :: ('MESH:D009901', 'Disease') :: ['glaucomatous optic neuropathy']
@entity1538 :: (MESH:D005902,Disease) :: ['Open-Angle Glaucoma']
